ZA200200692B - An improved amorphous form of cefpodoxime proxetil. - Google Patents
An improved amorphous form of cefpodoxime proxetil. Download PDFInfo
- Publication number
- ZA200200692B ZA200200692B ZA200200692A ZA200200692A ZA200200692B ZA 200200692 B ZA200200692 B ZA 200200692B ZA 200200692 A ZA200200692 A ZA 200200692A ZA 200200692 A ZA200200692 A ZA 200200692A ZA 200200692 B ZA200200692 B ZA 200200692B
- Authority
- ZA
- South Africa
- Prior art keywords
- cefpodoxime proxetil
- amorphous form
- solvent
- prepared
- mixtures
- Prior art date
Links
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 title claims description 33
- 229960004797 cefpodoxime proxetil Drugs 0.000 title claims description 33
- 238000000034 method Methods 0.000 claims description 23
- 239000002904 solvent Substances 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 8
- -1 chioroform Chemical compound 0.000 claims description 7
- 238000001694 spray drying Methods 0.000 claims description 7
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 150000002170 ethers Chemical class 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- 229940093499 ethyl acetate Drugs 0.000 claims 2
- 235000019439 ethyl acetate Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- JHBWYQRKOUBPCA-UHFFFAOYSA-N 1-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylurea Chemical compound S1C2=CC(OC)=CC=C2N=C1NC(=O)NC1=CC=CC=C1 JHBWYQRKOUBPCA-UHFFFAOYSA-N 0.000 description 1
- GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
- 240000005589 Calophyllum inophyllum Species 0.000 description 1
- 241000588652 Neisseria gonorrhoeae Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960005090 cefpodoxime Drugs 0.000 description 1
- WYUSVOMTXWRGEK-HBWVYFAYSA-N cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 229950008364 frentizole Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 229960003660 sertraline hydrochloride Drugs 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- JNMRHUJNCSQMMB-UHFFFAOYSA-N sulfathiazole Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CS1 JNMRHUJNCSQMMB-UHFFFAOYSA-N 0.000 description 1
- 229960001544 sulfathiazole Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1036DE1999 IN191496B (OSRAM) | 1999-07-30 | 1999-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200200692B true ZA200200692B (en) | 2003-05-28 |
Family
ID=11092065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200200692A ZA200200692B (en) | 1999-07-30 | 2002-01-25 | An improved amorphous form of cefpodoxime proxetil. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6602999B1 (OSRAM) |
| EP (1) | EP1204667A4 (OSRAM) |
| JP (1) | JP2003506329A (OSRAM) |
| CN (1) | CN1371381A (OSRAM) |
| AU (1) | AU5839100A (OSRAM) |
| BR (1) | BR0012865A (OSRAM) |
| IN (1) | IN191496B (OSRAM) |
| WO (1) | WO2001009143A1 (OSRAM) |
| ZA (1) | ZA200200692B (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT408226B (de) * | 1999-05-05 | 2001-09-25 | Biochemie Gmbh | Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2 |
| WO2002068429A1 (en) * | 2001-02-27 | 2002-09-06 | Ranbaxy Laboratories Limited | Process for the preparation of cefpodoxime proxetil |
| KR20070054730A (ko) * | 2004-10-18 | 2007-05-29 | 테바 파마슈티컬 인더스트리즈 리미티드 | 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법 |
| CA2609296A1 (en) * | 2005-05-16 | 2006-11-16 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising a cephalosporin |
| KR100840132B1 (ko) * | 2007-04-17 | 2008-06-23 | 재단법인서울대학교산학협력재단 | 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조 |
| AU2013316754A1 (en) * | 2012-09-11 | 2015-04-30 | Dr. Reddy's Laboratories Limited | Enzalutamide polymorphic forms and its preparation |
| EP4450130A3 (en) * | 2012-09-11 | 2025-01-08 | Medivation Prostate Therapeutics LLC | Formulations of enzalutamide |
| CN107427530B (zh) | 2015-03-06 | 2020-09-08 | 阿堤亚制药公司 | 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸 |
| WO2017046756A1 (en) * | 2015-09-18 | 2017-03-23 | Lupin Limited | Proxetil and axetil esters of cefixime |
| US11447506B2 (en) | 2016-05-09 | 2022-09-20 | Anacor Pharmaceuticals, Inc. | Crystal forms of crisaborole in free form and preparation method and use thereof |
| WO2017193914A1 (zh) * | 2016-05-09 | 2017-11-16 | 苏州科睿思制药有限公司 | 克立硼罗游离形式的晶型及其制备方法和用途 |
| CA3026885A1 (en) * | 2016-06-16 | 2017-12-21 | Xenon Pharmaceuticals Inc. | Solid state forms of spiro-oxindole compounds |
| EP3510021A1 (en) * | 2016-09-06 | 2019-07-17 | Indena S.p.A. | Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same |
| CN109689672B (zh) | 2016-09-07 | 2023-05-30 | 阿堤亚制药公司 | 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸 |
| US11369579B2 (en) | 2016-10-24 | 2022-06-28 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| US10336679B2 (en) * | 2016-10-24 | 2019-07-02 | Syneurx International (Taiwan) Corp. | Polymorphic forms of sodium benzoate and uses thereof |
| GEP20227457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
| US11053233B2 (en) * | 2017-03-30 | 2021-07-06 | Merck Patent Gmbh | Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol |
| LT3713919T (lt) * | 2017-11-22 | 2023-10-10 | Agios Pharmaceuticals, Inc. | Kristalinės n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)chinolin-8- sulfonamido formos |
| KR20210003780A (ko) * | 2018-04-05 | 2021-01-12 | 스미토모 다이니폰 파마 온콜로지, 인크. | Axl 키나제 억제제 및 그의 용도 |
| JP2021521118A (ja) | 2018-04-10 | 2021-08-26 | アテア ファーマシューティカルズ， インコーポレイテッド | 肝硬変を伴うｈｃｖ感染患者の治療 |
| CN110251467A (zh) * | 2019-06-26 | 2019-09-20 | 北京济美堂医药研究有限公司 | 一种无定形态头孢妥仑匹酯组合物的制备方法 |
| CN110437259B (zh) * | 2019-08-14 | 2021-12-07 | 中国药科大学 | 头孢泊肟酯柚皮素共无定形物及其制备方法 |
| JP2022551439A (ja) * | 2019-10-04 | 2022-12-09 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ａｘｌ阻害薬製剤 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| WO2022176017A1 (ja) * | 2021-02-16 | 2022-08-25 | 大塚製薬株式会社 | 非晶質体及び当該非晶質体を含む組成物 |
| KR20240022574A (ko) | 2021-06-17 | 2024-02-20 | 아테아 파마슈티컬즈, 인크. | 유리한 항-hcv 조합 요법 |
| JP7370029B1 (ja) | 2022-05-23 | 2023-10-27 | 国立大学法人 名古屋工業大学 | 湿式紡糸法を用いて製造された綿形状の骨再生材料、及び湿式紡糸法を用いて綿形状の骨再生材料を製造する方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4223153A (en) | 1979-02-09 | 1980-09-16 | Eli Lilly And Company | Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea |
| IT1165253B (it) | 1979-07-12 | 1987-04-22 | Blasinachim Spa | Procedimento di fabbricazione di acido chenodesossicolico cristallino puro |
| US4486425A (en) * | 1980-09-30 | 1984-12-04 | Sankyo Company Limited | 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates |
| YU44680B (en) | 1982-07-30 | 1990-12-31 | Glaxo Lab Ltd | Process for obtaining very pure amorphous form of cephuroxim axetile |
| IL100091A (en) | 1990-12-12 | 1998-08-16 | Zeneca Ltd | Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation |
| ES2215161T3 (es) * | 1991-09-07 | 2004-10-01 | Aventis Pharma Deutschland Gmbh | Diastereoisomero del ester 1-(isopropoxicarboniloxi)-etilico del acido 3-cefem-4-carboxilico y procedimiento para su preparacion. |
| US5248699A (en) | 1992-08-13 | 1993-09-28 | Pfizer Inc. | Sertraline polymorph |
| AT413383B (de) * | 1998-01-09 | 2006-02-15 | Sandoz Ag | Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil |
| KR100342943B1 (ko) * | 1999-08-04 | 2002-07-02 | 민경윤 | 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물 |
-
1999
- 1999-07-30 IN IN1036DE1999 patent/IN191496B/en unknown
-
2000
- 2000-07-24 US US10/048,354 patent/US6602999B1/en not_active Expired - Fee Related
- 2000-07-24 WO PCT/IB2000/001024 patent/WO2001009143A1/en not_active Ceased
- 2000-07-24 JP JP2001513950A patent/JP2003506329A/ja active Pending
- 2000-07-24 BR BR0012865-1A patent/BR0012865A/pt not_active Application Discontinuation
- 2000-07-24 CN CN00812246A patent/CN1371381A/zh active Pending
- 2000-07-24 AU AU58391/00A patent/AU5839100A/en not_active Abandoned
- 2000-07-24 EP EP00944159A patent/EP1204667A4/en not_active Withdrawn
-
2002
- 2002-01-25 ZA ZA200200692A patent/ZA200200692B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN191496B (OSRAM) | 2003-12-06 |
| WO2001009143A1 (en) | 2001-02-08 |
| CN1371381A (zh) | 2002-09-25 |
| US6602999B1 (en) | 2003-08-05 |
| EP1204667A4 (en) | 2002-10-30 |
| EP1204667A1 (en) | 2002-05-15 |
| AU5839100A (en) | 2001-02-19 |
| JP2003506329A (ja) | 2003-02-18 |
| BR0012865A (pt) | 2002-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200200692B (en) | An improved amorphous form of cefpodoxime proxetil. | |
| US6833452B2 (en) | Process for the preparation of highly pure crystalline (R,S)—cefuroxime axetil | |
| EP1619198B1 (en) | Process for the preparation of amorphous cefuroxime axetil | |
| CN101687884B (zh) | 大环内酯衍生物 | |
| WO2006024900A1 (en) | Highly pure cefditoren pivoxil | |
| US20220380304A1 (en) | Novel method for producing peramivir trihydrate, and water-based drying thereof | |
| EP1689755A2 (en) | Processes for the preparation of highly pure 3-(2-substituted vinyl) cephalosporin | |
| MXPA03003483A (es) | Procedimiento para la preparacion de acilfenilalaninas. | |
| CN103874692A (zh) | 卡巴他赛的无定形形式和用于其制备的方法 | |
| EP1185266A1 (en) | Amorphous form of fexofenadine hydrochloride | |
| WO2018029699A1 (en) | Solid state forms of (2e)-n-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide and process for preparation thereof | |
| US6858414B2 (en) | Multistage process for the preparation of highly pure deferoxamine mesylate salt | |
| WO2021117062A1 (en) | Process for the preparation of 4-[7-(6-Cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7- diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide and its polymorphs | |
| EP1590353B1 (en) | A process for the preparation of cefpodoxime proxetil | |
| CN112458141A (zh) | 一种3-羟甲基头孢噻肟的制备方法 | |
| CN113372368A (zh) | 一种弹性蛋白酶抑制剂前药及其用途 | |
| Rajan et al. | A PROCESS FOR THE PREPARATION OF SAMIDORPHAN AND ITS INTERMEDIATES | |
| WO2025104754A1 (en) | A process for the preparation of samidorphan and its intermediates | |
| JP2002205994A (ja) | セフジトレンピボキシル有機酸塩、無機酸塩、及びその製造方法 | |
| CN108640912A (zh) | 一种匹多莫德的工业化规模制备方法 | |
| WO2000077017A1 (en) | Novel amorphous form of clarithromycin | |
| CN101153044B (zh) | 广谱抗菌的含有硫基噻唑吡啶鎓甲基的头孢烯化合物 | |
| WO2022215083A1 (en) | Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof | |
| WO2011124992A1 (en) | Substantially pure strontium ranelate | |
| CA2380183A1 (en) | A process for the synthesis of beta-lactam derivatives |